DESTINY-Breast03 Phase 3 Study Results
Confirmed ORR
60
50
50
F
Confirmed Objective Response Rate
Hormone receptor-positive
| Hormone receptor-negative
52.6%a
3.6
50.0%
Complete Response
2.5
Partial Response
Percentage
40
40
30
30
49.2
16.3%
47.5
16.7%
20
20
0.6
5.6
10
10
15.7
11.1
0
T-DXD (n = 333)
TPC (n = 166)
Progressive disease, %
7.8
21.1
T-DXd (n = 40)
12.5
TPC (n = 18)
33.3
Not evaluable, %
4.2
12.7
7.5
5.6
Clinical benefit rate,b %
71.2
34.3
62.5
27.8
Duration of response, months
10.7
6.8
|
8.6
4.9
Hormone receptor status is based on data from the electronic data capture corrected for misstratification.
ORR, objective response rate; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
10
Daiichi-Sankyo
DESTINY-Breast04
*The response of 1 patient was not confirmed. Clinical benefit rate is defined as the sum of complete response rate, partial response rate, and more than 6 months' stable disease rate, based on blinded independent central review.
ASCO 2022 #LBA3 Plenary Session
16View entire presentation